N-Acetylcysteine Therapy in Thrombotic Thrombocytopenic Purpura: A Systematic Review and Critical Appraisal
Journal of Clinical Medicine · 03.04.2026 · 15 (7) · 2713
DOI: 10.3390/jcm15072713 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 03.04.2026. Verfasst von Ufuk Demirci und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Haematology, Medical Faculty, Manisa Celal Bayar University, 45030 Manisa, Türkiye. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Thrombotic thrombocytopenic purpura (TTP) is a life-threatening condition resulting from a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13 (ADAMTS13) deficiency, leading to the accumulation of ultra-large von Willebrand factor (vWF) multimers and widespread microvascular thrombosis. While therapeutic plasma exchange and immunosuppression have significantly improved response, refractory and relapsed disease are significant challenges. N-acetylcysteine (NAC) has emerged as a biologically plausible adjunctive therapy due to its potential to reduce disulfide bonds in vWF multimers. However, its clinical role is unclear. This systematic review aimed to evaluate the clinical evidence regarding the efficacy and safety of N-acetylcysteine in patients with immune-mediated TTP.
Methods
We performed a systematic review in accordance with the PRISMA guidelines. PubMed/MEDLINE, Google Scholar, and ClinicalTrials.gov were searched until January 2026. Studies involving patients with immune-mediated TTP treated with NAC were included. Case reports, case series, and observational studies involving patients with immune-mediated TTP treated with NAC were included. Risk of bias was evaluated using adapted quality assessment tools.
Results
Sixteen studies encompassing 69 patients met the inclusion criteria. Most reports were case reports or small case series; two were larger observational cohorts. NAC was predominantly used as adjunctive therapy in relapsed or refractory TTP. Dose regimens varied. Platelet recovery following NAC was reported within 1–15 days in responding cases. Predominantly positive haematological responses were observed in small series. Significant heterogeneity in patient populations, timing of initiation, concomitant therapies, and outcome reporting limited causal inference.
Conclusions
The current evidence suggests that NAC has a biologically rational and potentially adjunctive value in TTP, particularly in refractory disease or resource-constrained settings. However, current data are largely heterogeneous and derived from low-level evidence. Well-designed prospective studies and randomized controlled trials are needed to determine whether NAC provides significant clinical benefit beyond standard therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Haematology, Medical Faculty, Manisa Celal Bayar University, 45030 Manisa, Türkiye.
- Department of Internal Medicine, Medical Faculty, Manisa Celal Bayar University, 45030 Manisa, Türkiye.
- Department of Internal Medicine, Division of Haematology, Medical Faculty, Namık Kemal University, 59030 Tekirdağ, Türkiye.
ORCID-Profile: Ufuk Demirci, Zübeyir Talha Bilgin, Mehmet Baysal
Zitieren
APA
Demirci, U., Bilgin, Z. T., & Baysal, M. (2026). N-Acetylcysteine Therapy in Thrombotic Thrombocytopenic Purpura: A Systematic Review and Critical Appraisal. Journal of Clinical Medicine, 15(7), 2713. https://doi.org/10.3390/jcm15072713
Vancouver
Demirci U, Bilgin ZT, Baysal M. N-Acetylcysteine Therapy in Thrombotic Thrombocytopenic Purpura: A Systematic Review and Critical Appraisal. Journal of Clinical Medicine. 2026;15(7):2713. doi:10.3390/jcm15072713
BibTeX
@article{Demirci2026,
author = {Demirci, Ufuk and Bilgin, Zübeyir Talha and Baysal, Mehmet},
title = {N-Acetylcysteine Therapy in Thrombotic Thrombocytopenic Purpura: A Systematic Review and Critical Appraisal},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {7},
pages = {2713},
doi = {10.3390/jcm15072713}
}
EUVIMED